Serum and bronchial aspiration fluid HE-4 levels in lung cancer

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8795-8799

  Ucar, Elif Yilmazel ^a   Ozkaya, Alev Lazoglu ^a   Araz, Omer ^a   Akgun, Metin ^a   Meral, Mehmet ^a   Kaynar, Hasan ^a   Saglam, Leyla ^a   Aksoy, Hulya ^a   Akcay, Fatih ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

Bronchial aspiration fluid; Human epididymis 4; Lung cancer; Serum

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; WFDC2 PROTEIN, HUMAN;

ADULT; ARTICLE; BRONCHIAL ASPIRATION FLUID; BRONCHIAL ASPIRATION PROCEDURE; BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; LUNG CANCER; LUNG DISEASE; LUNG FLUID; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRANSBRONCHIAL BIOPSY; TUMOR LOCALIZATION; AGED; BLOOD; BODY FLUID; BRONCHUS; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG DISEASES; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; BODY FLUIDS; BRONCHI; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINS; ROC CURVE;

EID: 84919841853     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2134-3     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.
3. Roth K, Hardie JA, Andreassen AH, Leh F, Eagan TM. Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. MBC Pulm Med. 2007;8:2.
4. Baaklini WA, Reinoso MA, Gorin AB, Sharafkaneh A, Manian P. Diagnostic yield of fiberoptic bronchoscopy in evaluating solitary pulmonary nodules. Chest. 2000;117:1049–54.
5. Lee HS, Kwon SY, Kim KD, Yoon HI, Lee SM, Lee JH, et al. Determinants of diagnostic bronchial washing in peripheral lung cancer. Int J Tuberc Lung Dis. 2007;11:227–32.
6. Hirsch FR, Merrick DT, Franklin WA. Role of biomarker for early detection of lung cancer and chemoprevention. Eur Respir J. 2009;19:1151–8.
7. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 2006;7:167–74.
8. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4(WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768–73.
9. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45:350–7.
10. Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, et al. Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol Cancer Res Treat. 2009;8:323–32.
11. Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012;50:2181–8.
12. Molina R, Escudero JM, Auge JM, Filella X, Foj L, Torne A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biol. 2011;32:1087–95.
13. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.
14. Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:1573–8.
15. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–700.
16. Tokuishi K, Yamashita SI, Ohbo K, Kawahara K. Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma. Tumor Biol. 2012;33:103–9.
17. Detterbeck FC, Postmus PE, Tanoue LT. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e191S–210S.
18. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e142S–65S.
19. Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006;7:61.
20. Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.
21. Speeckaert MM, Speeckaert R, Delanghe JR. Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem. 2013;59:1–21.
22. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57:1534–44.
23. Yamashita S, Tokuishi K, Moroga T, Yamamoto S, Ohbo K, Miyahara S, et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression. Tumor Biol. 2012;33:2365–70.
24. Yamashita S, Tokuishi K, Hashimoto T, Moroga T, Kamei M, Ono K, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumor Biol. 2011;32:265–71.
25. Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumor Biol. 2012;33:1141–9.
26. Liu W, Yang J, Chi PD, Zheng X, Dai SQ, Chen H, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013;17:1346–53.